BBLG

Bone Biologics Corp (BBLG) | Rumor.io

Bone Biologics

BBLG

Attention (50-day avg)0%

Attention rank (50-day avg)#2,472

Bullish sentiment (50-day avg)41%

Price to earnings ratio0.08

Market capitalization1.4M

Earnings per share-0.28

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-3.1M

Social

What share of all stock conversation is about BBLG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Aug 12

Bone Biologics Corporation has achieved a 32-month validated shelf life for its rhNELL-1 protein, up from 29 months in May and 24 months in December.
This achievement supports lot sizing, inventory management, and distribution planning as the company approaches pivotal-study scale.
The updated shelf life is a positive operational milestone that improves manufacturing flexibility and preparation for future clinical development.

Generated by AI

Sentiment

Of the messages about BBLG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% new	5.88% -74.12	86.44% -4.86
Bearish	—	50% -50	94.12% +74.12	13.56% +4.86

Bullish· Aug 12

Bone Biologics' announcement of a 32-month validated shelf life for rhNELL-1 is a positive operational milestone that improves manufacturing flexibility and inventory management.
The company's small float and low market capitalization make it susceptible to significant price movements, which could be driven by positive clinical news or other catalysts.
The completion of enrollment in the NB1 first-in-human clinical trial, potential interim clinical updates, and additional regulatory/manufacturing milestones are all potential drivers of the stock's price in the near future.

Bearish· Sep 4

$BBLG's recent price action suggests a downtrend breakout, with a 1-minute close above $3.12.
The stock's inability to hold gains and its tendency to dump after a strong up day are indicative of a potential pump and dump scheme.
$BBLG's large volume and significant price drops are characteristic of a reverse split machine, suggesting a potential risk for investors.

Generated by AI

Topics

Of the messages about BBLG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	65.12%	70.78%
Technical Analysis	—	—	34.88%	28.57%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.65%

Announcements· Dec 23

Bone Biologics Corporation ($BBLG) has extended the shelf life of its lead product candidate, rhNELL-1, to 24 months, based on ongoing stability data.
The longer shelf life is expected to improve manufacturing efficiency, inventory management, and supply-chain flexibility as Bone Biologics advances rhNELL-1 through development.
Bone Biologics is focused on orthobiologic products for spinal fusion markets, with rhNELL-1 designed as a bone growth factor to support bone regeneration in fusion procedures.

Technical Analysis· Aug 1

$BBLG has support around 2.68-2.72 and may test 3.20.
The stock has broken resistance and may sustain its breakout, with a potential target of 3.70 and a subsequent test of 4.00.
$BBLG has strong premarket trend with extension targets of 4-4.20 and 4.50-.75+, with support at 3-3.15.

Generated by AI

Community

Of the messages about BBLG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	6.73%	19.81%
Newcomers	100%	100%	93.27%	80.19%

Regulars· Aug 12

The regulars are focusing on the operational milestone achieved by Bone Biologics, which is a 32-month validated shelf life for rhNELL-1, improving manufacturing flexibility and preparation for future clinical development.
The price action is seen as disconnected from the actual announcement, creating a potential buy-the-dip opportunity, and the catalysts that could move the stock are still ahead, including clinical trial completion, interim clinical updates, and regulatory milestones.
The regulars are speculating about the potential for the stock to surge, with some predicting a significant increase in price, while others are skeptical about the stock's prospects, with one calling it the "biggest fraud on the market".

Newcomers· Aug 12

Newcomers to Bone Biologics Corporation are excited about the company's achievement of a 32-month validated shelf life for its rhNELL-1 protein, citing improved manufacturing efficiency and supply chain flexibility.
Some newcomers are shorting the stock, citing the company's history of dilution and the recent good news as reasons to expect a drop in price.
Others are questioning the company's leadership, with one user calling the CEO "the quarterback" and implying that the company is in trouble.

Generated by AI

Addition of three sites strengthens expectation to complete enrollment by year-end 2026BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company’s rhNELL-1-based bone graft product for spinal fusion. Th

21d agoYahoo! Finance Canada

Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Jeff Frelick, Chief Executive Officer of Bone Biologics will hold one-on-one meetings with investors

26d agoYahoo! Finance Canada

BBLG Efficiency Improves as Crucial Trials Advance

1mo agoYahoo Finance

Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances

Bone Biologics has extended the validated shelf life of its rhNELL-1 protein to 32 months, giving the company greater manufacturing and supply-chain flexibility as it prepares for larger-scale clinical development and advances enrollment in its first-in-human NB1 study. Key Investor TakeawaysBone Biologics (NASDAQ:BBLG) has achieved a 32-month validated shelf life for rhNELL-1, extending the 29-month milestone reported in May 2026.

1mo agoYahoo Finance

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Bone Biologics (NASDAQ:BBLG), Definium T

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics

1mo agoBenzinga

Also Discussed

Investors talking about BBLG also mention

#	Name	Attention
1	Revelation Biosciences Inc.REVB	0%0
2	SMFL - Smart for Life, Inc.	——
3	Kidpik Corp.PIK	0%new
4	BranchOut Food Inc.BOF	0%0
5	Hour Loop, Inc.HOUR	0.01%0
6	SaverOne 2014 Ltd. ADRSVRE	0%new
7	Longeveron Inc. Class A Common StockLGVN	0%0
8	Dermata Therapeutics, Inc.DRMA	0%new
9	GRCL - Gracell Biotechnologies Inc.	——
10	FWBI - First Wave BioPharma, Inc.	——

Bone Biologics Corp

Healthcare
Biotechnology

Bone Biologics Corp is a clinical-stage medical device company focused on orthobiologic products for spinal fusion and bone regeneration. The company’s current work centers on NELL-1, a recombinant human protein used with demineralized bone matrix to support targeted bone healing in lumbar spinal fusion procedures. Its product development is aimed at improving outcomes in skeletal repair, with applications that extend across spinal, orthopedic, reconstructive, neurosurgical, and sports medicine settings. Bone Biologics Corp operates in the healthcare technology and medical specialties space, where orthobiologics play an important role in supporting bone growth and repair during surgery. Headquartered in Burlington, Massachusetts, Bone Biologics Corp is positioned as a developer of regenerative solutions for surgeons and medical centers working with complex bone-related procedures.

Website

Location

2 Burlington Woods Drive

Burlington, MA, 01803

United States

Social

What share of all stock conversation is about BBLG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Aug 12

Bone Biologics Corporation has achieved a 32-month validated shelf life for its rhNELL-1 protein, up from 29 months in May and 24 months in December.
This achievement supports lot sizing, inventory management, and distribution planning as the company approaches pivotal-study scale.
The updated shelf life is a positive operational milestone that improves manufacturing flexibility and preparation for future clinical development.

Generated by AI

Sentiment

Of the messages about BBLG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% new	5.88% -74.12	86.44% -4.86
Bearish	—	50% -50	94.12% +74.12	13.56% +4.86

Bullish· Aug 12

Bone Biologics' announcement of a 32-month validated shelf life for rhNELL-1 is a positive operational milestone that improves manufacturing flexibility and inventory management.
The company's small float and low market capitalization make it susceptible to significant price movements, which could be driven by positive clinical news or other catalysts.
The completion of enrollment in the NB1 first-in-human clinical trial, potential interim clinical updates, and additional regulatory/manufacturing milestones are all potential drivers of the stock's price in the near future.

Bearish· Sep 4

$BBLG's recent price action suggests a downtrend breakout, with a 1-minute close above $3.12.
The stock's inability to hold gains and its tendency to dump after a strong up day are indicative of a potential pump and dump scheme.
$BBLG's large volume and significant price drops are characteristic of a reverse split machine, suggesting a potential risk for investors.

Generated by AI

Topics

Of the messages about BBLG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	65.12%	70.78%
Technical Analysis	—	—	34.88%	28.57%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.65%

Announcements· Dec 23

Bone Biologics Corporation ($BBLG) has extended the shelf life of its lead product candidate, rhNELL-1, to 24 months, based on ongoing stability data.
The longer shelf life is expected to improve manufacturing efficiency, inventory management, and supply-chain flexibility as Bone Biologics advances rhNELL-1 through development.
Bone Biologics is focused on orthobiologic products for spinal fusion markets, with rhNELL-1 designed as a bone growth factor to support bone regeneration in fusion procedures.

Technical Analysis· Aug 1

$BBLG has support around 2.68-2.72 and may test 3.20.
The stock has broken resistance and may sustain its breakout, with a potential target of 3.70 and a subsequent test of 4.00.
$BBLG has strong premarket trend with extension targets of 4-4.20 and 4.50-.75+, with support at 3-3.15.

Generated by AI

Community

Of the messages about BBLG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	6.73%	19.81%
Newcomers	100%	100%	93.27%	80.19%

Regulars· Aug 12

The regulars are focusing on the operational milestone achieved by Bone Biologics, which is a 32-month validated shelf life for rhNELL-1, improving manufacturing flexibility and preparation for future clinical development.
The price action is seen as disconnected from the actual announcement, creating a potential buy-the-dip opportunity, and the catalysts that could move the stock are still ahead, including clinical trial completion, interim clinical updates, and regulatory milestones.
The regulars are speculating about the potential for the stock to surge, with some predicting a significant increase in price, while others are skeptical about the stock's prospects, with one calling it the "biggest fraud on the market".

Newcomers· Aug 12

Newcomers to Bone Biologics Corporation are excited about the company's achievement of a 32-month validated shelf life for its rhNELL-1 protein, citing improved manufacturing efficiency and supply chain flexibility.
Some newcomers are shorting the stock, citing the company's history of dilution and the recent good news as reasons to expect a drop in price.
Others are questioning the company's leadership, with one user calling the CEO "the quarterback" and implying that the company is in trouble.

Generated by AI

Bone Biologics

Social

Aug 12

Bullish· Aug 12

Bearish· Sep 4

Announcements· Dec 23

Technical Analysis· Aug 1

Regulars· Aug 12

Newcomers· Aug 12

Bone Biologics expands Australian trial to six hospital sites

Bone Biologics Expands Trial Sites

Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BBLG Efficiency Improves as Crucial Trials Advance

Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Bone Biologics (NASDAQ:BBLG), Definium T

Also Discussed

Bone Biologics Corp

Company Information

Location

Bone Biologics expands Australian trial to six hospital sites

Bone Biologics Expands Trial Sites

Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BBLG Efficiency Improves as Crucial Trials Advance

Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Bone Biologics (NASDAQ:BBLG), Definium T

Also Discussed

Social

Aug 12

Bullish· Aug 12

Bearish· Sep 4

Announcements· Dec 23

Technical Analysis· Aug 1

Regulars· Aug 12

Newcomers· Aug 12